Ignacio I. Wistuba - Concepedia

Author

Ignacio I. Wistuba

The University of Texas MD Anderson Cancer Center ORCID

Also Known As

Alexandre Reuben, Arvind Rao, David Elashoff, Geisinger, Kim R., Grande-Allen, K. Jane, Hojabr Kakavand, I I Wistuba, I WISTUBA, I Wistuba, I. I. Wistuba

2.8K

Publications

102.9K

Citations

153

H-Index

227

Concepts

All Affiliations

The University of Texas MD Anderson Cancer Center The University of Texas Southwestern Medical Center Memorial Sloan Kettering Cancer Center Baylor College of Medicine Dana-Farber Cancer Institute

About

Ignacio I. Wistuba is an author at The University of Texas MD Anderson Cancer Center specializing in medicine, lung cancer, and tumor biology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	92	284	34.9K
2	Health Sciences	28	37	5.2K
3	Engineering	17	18	1.6K
4	Public Health	3	3	210
5	Natural Sciences	2	2	334

Ignacio I. Wistuba

639

Publications

78.9K

Citations

144

H-Index

Page 1

	Year	Citations
Somatic mutations affect key pathways in lung adenocarcinoma Li Ding, Gad Getz, David A. Wheeler, Nature Somatic VariantSomatic MutationsBronchial NeoplasmCancer GeneticsSystems Biology	2008	2.7K
Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs Mark G. Kris, Bruce E. Johnson, Lynne D. Berry, JAMA	2014	1.7K
<i>STK11/LKB1</i> Mutations and PD-1 Inhibitor Resistance in <i>KRAS</i>-Mutant Lung Adenocarcinoma Ferdinandos Skoulidis, Michael E. Goldberg, Danielle Greenawalt, Cancer Discovery	2018	1.5K
Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial Hussein A. Tawbi, Melissa Burgess, Vanessa Bolejack, The Lancet Oncology OncologyPathologyAdvanced Soft-tissue SarcomaBone SarcomaImmune Checkpoint Inhibitor	2017	1.4K
Characterizing the cancer genome in lung adenocarcinoma Barbara A. Weir, Michele Sue‐Ann Woo, Gad Getz, Nature	2007	1.1K
An Epithelial–Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl as a Therapeutic Target for Overcoming EGFR Inhibitor Resistance Lauren A. Byers, Lixia Diao, Jing Wang, Clinical Cancer Research	2012	1.1K
Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing Jianjun Zhang, Junya Fujimoto, Jianhua Zhang, Science Cancer Gene MutationsPathologyMultiregion SequencingTumor BiologyLung Cancers	2014	975
Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade Pei-Ling Chen, Whijae Roh, Alexandre Reuben, Cancer Discovery	2016	971
Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression Limo Chen, Don L. Gibbons, Sangeeta Goswami, Nature Communications Intratumoral ImmunosuppressionMicrorna-200/zeb1 Axis ControlMedicineImmunologyTumor Immunity	2014	970
Co-occurring Genomic Alterations Define Major Subsets of <i>KRAS</i> -Mutant Lung Adenocarcinoma with Distinct Biology, Immune Profiles, and Therapeutic Vulnerabilities Ferdinandos Skoulidis, Lauren A. Byers, Lixia Diao, Cancer Discovery	2015	883

Page 1